Opioid Use Disorder Drugs Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Agonist Drugs, Antagonist Drugs, Others), By Route of Administration (Oral, Parenteral, Sublingual, Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Opioid Use Disorder (OUD) Drugs Market is projected to expand robustly from USD 3.89 Billion in 2025 to USD 6.81 Billion by 2031, at a Compound Annual Growth Rate of 9.78%. This market encompasses pharmaceutical formulations like buprenorphine, methadone, and naltrexone, which are vital for managing opioid dependence by alleviating withdrawal symptoms and reducing cravings. Market growth is primarily driven by the escalating prevalence of opioid addiction, coupled with substantial increases in government funding dedicated to medication-assisted treatment (MAT) programs. The urgent need for effective therapeutic interventions is underscored by statistics showing a 536 percent rise in workplace overdose fatalities since 2011 by 2026. Moreover, the expanding adoption of evidence-based MAT models, combining behavioral therapy with pharmacotherapy, has significantly propelled demand, leading to over 650,000 individuals receiving OUD medications and contributing to a provisional 27 percent decrease in annual drug overdose deaths in the U.S. by 2024, emphasizing the market's critical role in public health improvement.
Market Driver
Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.
Market Challenge
Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.
Market Trends
Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.
Key Market Players
* Indivior PLC
* Alkermes plc
* Braeburn Pharmaceuticals, Inc.
* Novartis AG
* Purdue Pharma L.P.
* Mallinckrodt Pharmaceuticals
* Johnson & Johnson Services, Inc.
* Pfizer Inc.
* Lundbeck A/S
* Titan Pharmaceuticals, Inc.
Report Scope
In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Opioid Use Disorder Drugs Market, By Drug Type
* Agonist Drugs
* Antagonist Drugs
* Others
# Opioid Use Disorder Drugs Market, By Route of Administration
* Oral
* Parenteral
* Sublingual
* Nasal
# Opioid Use Disorder Drugs Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Opioid Use Disorder Drugs Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.
Available Customizations:
Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Opioid Use Disorder Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Opioid Use Disorder Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Opioid Use Disorder Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Opioid Use Disorder Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Opioid Use Disorder Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Opioid Use Disorder Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Opioid Use Disorder Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Opioid Use Disorder Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Opioid Use Disorder Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Opioid Use Disorder Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Opioid Use Disorder Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Opioid Use Disorder Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Opioid Use Disorder Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Opioid Use Disorder Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Opioid Use Disorder Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Opioid Use Disorder Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
10. South America Opioid Use Disorder Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Opioid Use Disorder Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Opioid Use Disorder Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Opioid Use Disorder Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Indivior PLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Alkermes plc
15.3. Braeburn Pharmaceuticals, Inc.
15.4. Novartis AG
15.5. Purdue Pharma L.P.
15.6. Mallinckrodt Pharmaceuticals
15.7. Johnson & Johnson Services, Inc.
15.8. Pfizer Inc.
15.9. Lundbeck A/S
15.10. Titan Pharmaceuticals, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們